Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
February 21, 2023
End-tidal carbon dioxide measured at emergency department triage outperforms standard triage vital signs in predicting in-hospital mortality and intensive care unit admission
Jay G Ladde, Stacie Miller, Kevin Chin, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
December 31, 2021
Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab
Nadia Terranova, Jonathan French, Haiqing Dai, et al.
Digestive Diseases and Sciences
|
November 11, 2025
Fistula Outcomes After Seton Removal in Patients with Perianal Fistulizing Crohn's Disease: A Systematic Review and Meta-Analysis
Edgard Medawar, Kevin Chin Koon Siw, Amine Zoughlami, et al.
Respirology Case Reports
|
November 6, 2025
Bronchial Artery-Pulmonary Artery Fistula With Dual Arterial Feeders Treated Successfully With Staged Embolisation Procedures-A Case Report
Hei-Shun Cheng, James Fung, K M Cyrus Mo, et al.
Future Oncology (London, England)
|
March 31, 2022
Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors
Yi-Long Wu, Ying Cheng, Huajun Chen, et al.
Journal for Immunotherapy of Cancer
|
January 18, 2019
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
Ulrich Keilholz, Janice M Mehnert, Sebastian Bauer, et al.
The Lancet. Oncology
|
April 5, 2017
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
James L Gulley, Arun Rajan, David R Spigel, et al.
The Lancet. Oncology
|
December 17, 2009
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D Wolchok, Bart Neyns, Gerald Linette, et al.
The Lancet. Oncology
|
December 13, 2021
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Vivek Naranbhai, Mathias Viard, Michael Dean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2017
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
February 21, 2023
End-tidal carbon dioxide measured at emergency department triage outperforms standard triage vital signs in predicting in-hospital mortality and intensive care unit admission
Jay G Ladde, Stacie Miller, Kevin Chin, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
December 31, 2021
Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab
Nadia Terranova, Jonathan French, Haiqing Dai, et al.
Digestive Diseases and Sciences
|
November 11, 2025
Fistula Outcomes After Seton Removal in Patients with Perianal Fistulizing Crohn's Disease: A Systematic Review and Meta-Analysis
Edgard Medawar, Kevin Chin Koon Siw, Amine Zoughlami, et al.
Respirology Case Reports
|
November 6, 2025
Bronchial Artery-Pulmonary Artery Fistula With Dual Arterial Feeders Treated Successfully With Staged Embolisation Procedures-A Case Report
Hei-Shun Cheng, James Fung, K M Cyrus Mo, et al.
Future Oncology (London, England)
|
March 31, 2022
Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors
Yi-Long Wu, Ying Cheng, Huajun Chen, et al.
Journal for Immunotherapy of Cancer
|
January 18, 2019
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
Ulrich Keilholz, Janice M Mehnert, Sebastian Bauer, et al.
The Lancet. Oncology
|
April 5, 2017
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
James L Gulley, Arun Rajan, David R Spigel, et al.
The Lancet. Oncology
|
December 17, 2009
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D Wolchok, Bart Neyns, Gerald Linette, et al.
The Lancet. Oncology
|
December 13, 2021
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Vivek Naranbhai, Mathias Viard, Michael Dean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2017
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, et al.
Page
of 4